IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 87.6% in June

IceCure Medical Ltd. (NASDAQ:ICCM) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 89,416 shares, a decline of 87.6% from the May 31st total of 718,392 shares. Based on an average daily volume of 160,692 shares, the short-interest ratio is presently 0.6 days. Approximately 3.3% of the shares of the stock are short sold.

IceCure Medical Trading Down 15.1%

ICCM stock traded down $1.06 during midday trading on Friday, hitting $5.96. The company had a trading volume of 771,920 shares, compared to its average volume of 10,011,018. IceCure Medical has a 52 week low of $2.12 and a 52 week high of $42.00. The stock’s 50 day moving average price is $6.68 and its 200 day moving average price is $13.78. The stock has a market cap of $16.73 million, a price-to-earnings ratio of -0.83 and a beta of 0.40.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $1.34 million. Analysts predict that IceCure Medical will post -3.51 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Alliance Global Partners initiated coverage on IceCure Medical in a research report on Monday, May 4th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Finally, Maxim Group reduced their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $62.70.

Institutional Trading of IceCure Medical

Institutional investors have recently modified their holdings of the company. Concurrent Investment Advisors LLC bought a new position in IceCure Medical during the 4th quarter valued at approximately $48,000. Jane Street Group LLC bought a new stake in shares of IceCure Medical in the 4th quarter worth approximately $67,000. Finally, Virtu Financial LLC purchased a new position in shares of IceCure Medical during the fourth quarter valued at approximately $39,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical News Roundup

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: IceCure Medical said it has regained compliance with Nasdaq’s minimum bid price requirement, removing a near-term listing concern that can often pressure small-cap stocks. IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: Brookline Capital Markets raised near-term and mid-term EPS estimates for IceCure Medical, including higher forecasts for Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting a slightly better outlook for profitability trends. Icecure Medical Earnings Estimates, EPS & Revenue | NASDAQ:ICCM
• Neutral Sentiment: Short interest fell sharply in mid-June, which can reduce bearish pressure, although there was also a conflicting data entry showing zero shares short, making the signal somewhat unclear.
• Neutral Sentiment: The latest analyst revisions still point to significant losses in the coming years, even though the estimates improved in several periods. This keeps the stock’s longer-term valuation story uncertain.
• Negative Sentiment: IceCure remains unprofitable, and the company previously reported a quarterly EPS loss that missed expectations along with revenue below estimates, which likely continues to weigh on investor sentiment.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.